Navigation Links
AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
Date:10/29/2008

Alliance extended for a further five years

WILMINGTON, Del. and HOUSTON, Oct. 29 /PRNewswire/ -- AstraZeneca and The University of Texas M. D. Anderson Cancer Center today announced they have renewed their collaboration to integrate pre-clinical and clinical research with a view to speeding up access to new medicines of potential benefit to cancer patients.

The collaboration facilitates interactions between physicians and scientists in both organizations to combine resources and expertise in disease intervention whilst providing flexibility to work in a variety of ways and accelerate the development of new treatments. It is unusual in its focus on pre-clinical research and the transition to clinical trials and was the first of its kind for both institutions.

Since its launch in 2005, the collaboration has utilized AstraZeneca's early development portfolio to generate over two dozen joint research projects. Both parties intend to build on these by extending the collaboration for a further five years and broadening its original focus from aerodigestive diseases (head and neck cancers and lung cancer) to include targets with potential in a variety of cancer settings.(1)

Brent Vose, Vice President of AstraZeneca's Oncology Therapy Area said: "AstraZeneca is committed to the research and development of new, targeted anti-cancer therapies to improve the lives of cancer patients.

"We have a number of promising compounds in development and look forward to seeing the results of some key studies throughout the next year.

"Our collaboration with M.D. Anderson has proven our ability to speed up the drug development process without compromising quality and we look forward to building on our joint efforts to date."

Close cooperation in areas of common interest is essential to meet the challenge of safe, accelerated drug development according to Robert C. Bast Jr., M.D., Vice President for Translational Research
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
2. Melior Enters Research Collaboration with AstraZeneca
3. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
4. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
5. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
6. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
7. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
8. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
9. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
10. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
11. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Xencor, Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... appointment of Debra Zack , M.D., Ph.D., ... Lloyd Rowland , senior vice president, chief ... "Debra,s expertise in biologics clinical development and medical ...
(Date:9/2/2014)... Winston-Salem, NC and Rocky Mount, NC (PRWEB) September 02, ... (PMG) announced today the establishment of its 11th clinical ... 1, PMG Research has assumed ownership and operation of ... in Rocky Mount, NC, further expanding PMG’s presence in ... to an additional 130,000 patients. For the patients in ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue: India Solid Waste Management Vehicles ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... governing bodies responsible for complete handling and regulation ... average, around 135,000 MT solid waste is generated ...
(Date:8/31/2014)... Available spectra is similar for all L-series products ... a wide range of plants. The spectra is ... and pending wide spectrum technology. The single chip ... in contrast to growth spectra made from monochromatic ... large variety of differently sized and shaped growing ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:9/1/2014)... decisions of the Nomenclature Section of the XVIII International ... 2011. This meeting is held every six years and ... rules for naming algae, fungi and plants get together ... the organisms they study. This is the primary product ... algae, fungi, and plants, which was published in 2012. ...
(Date:8/31/2014)... fast and accurate tool to diagnose tuberculosis in ... developed test (TAM-TB assay) is the first reliable ... The test features excellent specificity, a similar sensitivity ... a blood test. The promising findings are a ... children, particularly in tuberculosis-endemic regions. , The study ...
(Date:8/31/2014)... of the greatest challenges in modern medicine is developing ... with minimal toxicity and side-effects to the patient. Such ... the drug molecule. Ideally, the drug should have a ... so that it binds it with high specificity. Publishing ... a synthetic amino acid that can impact the 3D ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2New tuberculosis blood test in children is reliable and highly specific 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... WORCESTER, Mass. Orthopedic surgeons are often hamstrung ... bone injuries resulting from trauma, aging or cancer. Conventional ... or brittle ceramics, and cannot readily conform to the ... in addition, they often require metallic fixation devices that ...
... Swiss needle cast epidemic in Douglas-fir forests of the coastal ... over at least the past 100 years, and is probably ... and a warmer climate, new research concludes. Scientists in ... found that this disease, which is affecting hundreds of thousands ...
... the University of Alabama at Birmingham (UAB) have been ... Scholarship and Excellence in Education Foundation. Atbin Doroodchi, ... Biology and Mathematics. He has a 3.95 grade-point average ... Honors Program. Doroodchi is an undergraduate researcher in the ...
Cached Biology News:Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers 2Forest epidemic is unprecedented phenomenon, still getting worse 2Forest epidemic is unprecedented phenomenon, still getting worse 3Forest epidemic is unprecedented phenomenon, still getting worse 43 UAB students awarded prestigious Goldwater scholarships 2
... Clone/PAD: ZMD.358. Immunogen: Synthetic ... region of human mouse and ... with human and mouse LRP5 ... (positive controls: mouse LRP5-pSEC-tag-transfected 293T ...
MarrowMAX Bone Marrow Medium...
... recognizes murine IRF7 protein, and ... related IRF proteins. Reactivity of ... protein was confirmed by western ... cells transfected with IRF7. Reactivity ...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
Biology Products: